Trade Summary

4 days ago, Dulac Edward J III, serving as EVP, Chief Financial Officer at Intellia Therapeutics, Inc. (NTLA), sold 8,111 shares at $11.25 per share, for a total transaction value of $91,248.75. Following this transaction, Dulac Edward J III now holds 148,175 shares of NTLA.

This sale represents a 5.19% decrease in Dulac Edward J III's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, July 22, 2026 and publicly disclosed via SEC Form 4 filing on Friday, July 24, 2026 at 5:26 PM ET, 2 days after the trade was made.

Intellia Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.